Acute cardiac care & resuscitation
Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the Danish-German (DanGer) Shock Randomized Clinical Trial
Authors' conclusion
Use of a MAFP reduces the use of vasopressors and inotropic medication while maintaining hemodynamic stability and achieving faster normalization of lactate level in patients with STEMI-CS.
Study context
- Population
- STEMI with cardiogenic shock (SBP <100 mm Hg or vasopressors, LVEF <45%, arterial lactate >2.5 mmol/L), 14 heart centres in Denmark, Germany and the UKof 355 enrolled
- Participants
- 324 participants
- Comparison
- Microaxial flow pump (MAFP) plus standard care vs standard care alone
- MAFPn = 169
- Standard caren = 155reference
- Primary endpoint
- Hemodynamic status (heart rate, BP), arterial lactate and vasoactive-inotropic score (VIS)
Methodological detailsinternational, multicentre, open-label
- International
- Multicentre
- Open-label
Primary result
As reported in the abstract
MAFP vs Standard careMean difference, mmol/L (95% CI)
Arterial lactate on ICU arrival, lower with MAFP; persisted through first 24 h
1.3(0.7–1.9)
MAFP vs Standard careDifference, hours (95% CI)
Lactate normalization (<2 mmol/L) earlier with MAFP
12(5–18)
Original publication
Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical Trial. JAMA Cardiol. Published 1 January 2025. doi:10.
Summarised from the published abstract; every number is checked against it